英语翻译For the first six months of 2009,the Group’s total reven

英语翻译
For the first six months of 2009,the Group’s total revenue was mainly boosted by a
195.0% surge in sales of biological drugs to RMB27.4 million,compared to RMB9.3
million in HY2008 as the Group only commenced biological drug sales in March
2008.In 2Q2009 alone,the biological drug sales of RMB13.3 million achieved
represent a 53.3% increase over the RMB8.7 million biological drug sales a year ago.
Approximately RMB11.2 million of the year-to-date biological drug sales were
realised through the Group’s extensive network of customers (which comprises 5,400
animal drug retailers and over 20 large poultry corporations),and the remaining
RMB16.2 million via sales of swine fever vaccines to provincial veterinary stations.
Sale of powdered form drugs rebounded strongly to RMB78.7 million in 2Q2009,
representing a staggering 43.3% increase over the preceding quarter,as the spillover
effects of the bird flu scare in December 2008 faded during the second quarter.
While this segment only increased 0.8% period-on-period,it is a significant
improvement compared to the 20.1% decrease recorded for 1Q2009 on 1Q2008.The
strong performance in 2Q2009 has also helped to narrow the year-to-date decrease in
powdered form drug sales to 9.0%.For HY2009,the Group recorded RMB133.6
million of sales from powdered form drugs.

2009年上半年,生物药品销售激增195%,集团相关的总收益达到了2740万元人民币,而去年同期,由于生物药品从三月份才开始销售,相应的收益仅为930万元.单独来看2009年二季度的情况,实现生物药品销售收入1330万元,比去年同期的销售额870万元增加了53.3%.
从年初到现在,约有1120万元的生物药品销售收入是通过集团广泛的顾客销售网络实现的（网络包括5400个动物药品零售商和超过20家的大型禽业公司）,余下的1620万则是通过政府的兽医站以猪瘟疫苗的方式销售的.
2009年第二季度,药粉销售额强势反弹至7870万元人民币,和一季度相比,在08年12月份由禽流感恐慌带来的销售刺激逐渐消退的情况下,二季度销售额依然取得了令人鼓舞的43.3%的增长.虽然同比只有0.8%的增长,但是和相对于一季度同比20.1%的销售滑坡而言,这已经是非常出色的了.二季度的强势表现也将上半年药粉销售的同比降幅缩小为9%.2009年上半年,集团粉状药物的销售额为1亿3360万元.